Press Releases

Sergey Kostikov Sergey Kostikov

Traws Pharma Reports Full Year 2024 Results and Business Highlights

Traws Pharma, Inc. today reported financial results for the year ended December 31, 2024 and provided recent business highlights, with updates to the Company’s investigational programs including lead product candidate, tivoxavir marboxil (TXM) in development for bird flu, and ratutrelvir in development for COVID.

Read More
Sergey Kostikov Sergey Kostikov

Traws Pharma Announces Management Updates

Traws Pharma, Inc. today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer (CEO), effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assume the role of Interim CEO. In addition to his new responsibilities, Dr. Dukes will continue to serve as Traws’ Chairman.

Read More
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
Maria Parshenkova Maria Parshenkova

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Traws Pharma, Inc. today announced the appointment of Luba Greenwood as Director. In addition, Director James J. Marino is stepping down after nearly ten years of dedicated service, including four years as Chairman, due to other professional commitments.

Read More
Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate
Maria Parshenkova Maria Parshenkova

Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate

NEWTOWN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”) today announced presentation of a poster at the annual International Conference on Antiviral Research (ICAR2024) which is being held from May 20th to May 24th in Gold Coast, Australia.

Read More
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
Maria Parshenkova Maria Parshenkova

Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy

NEWTOWN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, today announced that it completed dosing in the first cohort of the first-in-human Phase 1 study to evaluate travatrelvir (TRX01), an orally-available protease inhibitor, in development for treatment of COVID19.

Read More
To access Press Release Archive, click here.